Overview

Zoledronic Acid for Prevention of Bone Loss After BAriatric Surgery (ZABAS)

Status:
Recruiting
Trial end date:
2024-06-01
Target enrollment:
0
Participant gender:
All
Summary
In a randomised placebo-controlled trial assess effects of zoledronic acid for prevention of bone and muscle loss after bariatric surgery.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Stinus Gadegaard Hansen
Collaborators:
Department of Endocrinology, Odense University Hospital, Odense, Denmark
Department of Radiology and Nuclear Medicine, Hospital of Southwest Jutland, 6700 Esbjerg, Denmark
Department of Regional Health Research, University of Southern Denmark
Odense University Hospital
OPEN - Odense Patient data Explorative Network, The University of Southern Denmark, Odense, Denmark
Research Unit of Health Sciences, Hospital of South West Jutland
Treatments:
Zoledronic Acid
Criteria
Inclusion Criteria:

- 35 years old or older

- Eligible for bariatric surgery (BMI>35 kg/m2 with obesity-related comorbidity)

Exclusion Criteria:

- Pregnancy or breastfeeding.

- Chronic kidney disease with estimated GFR<45 ml/min.

- Hypocalcemia .

- Hypersensitivity to bisphosphonates, mannitol, sodium citrate or water.

- Metabolic bone disease (osteoporosis is allowed).

- Prior treatment with anti-osteoporotic agents.

- Treatment with oral glucocorticoids

- Other diseases with known effects on bone metabolism